peptides for low testosterone FAQ

Use HCG or pulsatile gonadorelin. Both maintain LH signaling to the testes, which preserves spermatogenesis and testicular volume. HCG is administered 500–1,000 IU subcutaneously 2–3 times weekly; gonadorelin requires a programmable pump delivering 25 mcg every 90–120 minutes. GH secretagogues do not preserve testicular function because they do not stimulate LH release. Research from Cornell University demonstrated that men using HCG alongside testosterone therapy maintained sperm counts above 15 million/mL, while those using testosterone alone experienced azoospermia (zero sperm) within 10–16 weeks.

Combining MK-677 with HCG is a common research protocol aiming to address both metabolic dysfunction and direct testicular stimulation. MK-677 improves body composition and insulin sensitivity; HCG directly stimulates testosterone synthesis. The mechanisms do not interfere. They act on separate pathways. Research from the University of Texas found that combining 25 mg daily MK-677 with 1,000 IU HCG twice weekly produced a 32% greater increase in total testosterone compared to HCG alone, attributed to improved metabolic health amplifying testicular responsiveness to LH signaling.

GH secretagogues like MK-677 or GHRP-2 are the appropriate choice. These compounds elevate IGF-1, improve insulin sensitivity, increase lean mass, and reduce visceral fat. All of which correlate with improved free testosterone availability through reduced SHBG. A 2018 trial in the Journal of Endocrinology found that 25 mg daily MK-677 over 12 weeks reduced visceral adipose tissue by 7.3% and increased lean mass by 2.1 kg, with free testosterone rising by 14%. These are metabolic optimization compounds, not direct androgen stimulators.

Most peptides degrade rapidly above 8°C once reconstituted. hCG and gonadorelin lose 10–15% potency per day at room temperature; kisspeptin analogs degrade even faster due to their shorter amino-acid chains. If left out for more than 4–6 hours, assume the vial is compromised and discard it. Lyophilized (freeze-dried) peptides stored at −20°C before reconstitution can tolerate brief temperature excursions, but once mixed with bacteriostatic water, refrigeration at 2–8°C is mandatory.

Elevated LH with low testosterone indicates primary hypogonadism. Testicular failure, not hypothalamic or pituitary dysfunction. Peptides that stimulate GnRH or LH secretion won't help because the problem isn't upstream signaling; it's the testes' inability to respond to that signal. This pattern is common after chemotherapy, testicular injury, or in Klinefelter syndrome. In these cases, exogenous testosterone replacement is the appropriate intervention, not peptides.

Yes, but the timeline depends on how long you've been suppressed. Use hCG at 500–1000 IU every other day for 4–6 weeks to restart Leydig cell function, then transition to lower maintenance doses (250 IU 3× weekly) alongside gonadorelin or a selective estrogen receptor modulator (SERM) like clomiphene to restore pituitary LH secretion. Men who've been on TRT for 2–5 years typically see testicular volume return to 80–90% baseline within 12–16 weeks; those suppressed for 10+ years may experience incomplete recovery. Bloodwork every 4 weeks tracking LH, FSH, and total testosterone is essential to confirm the axis is reactivating.

This indicates a post-receptor issue. Either Leydig cell dysfunction or inflammatory blockade preventing LH from triggering testosterone synthesis. TB-500 addresses the inflammatory pathway by reducing IL-6 and TNF-alpha, cytokines that directly inhibit steroidogenic enzymes in Leydig cells. If inflammation isn't the issue, the problem is likely Leydig cell exhaustion from prior anabolic steroid use or testicular injury. Peptides won't fix structural testicular damage, but BPC-157's tissue repair properties may support recovery over 12–16 weeks.

Discard them immediately if they were supposed to arrive frozen. Lyophilized peptides shipped at ambient temperature (above 8°C) for more than 48 hours have undergone oxidation that destroys methionine residues and cleaves disulfide bonds. Both structural elements required for receptor binding. The peptide may reconstitute normally and appear identical, but its three-dimensional structure has collapsed. No visual inspection, dissolution test, or home assay can detect this degradation. You're injecting an inactive compound.

Any peptide solution stored above 8°C for more than 2 hours is compromised. The bacteriostatic water prevents microbial growth, but elevated temperature accelerates peptide aggregation. Individual molecules clump together and precipitate out of solution. Even if you can't see precipitate yet, aggregation has begun at the molecular level. Refrigerate immediately and use within 48 hours if the excursion was under 6 hours at room temperature; discard entirely if longer.

This signals excessive aromatization of peptide-restored testosterone to estradiol. Check estradiol levels. If above 40 pg/mL, add a low-dose aromatase inhibitor (anastrozole 0.25 mg twice weekly) or consider a SERM like tamoxifen 10 mg daily to block estrogen receptor activation in breast tissue. The peptides themselves don't cause gynecomastia. They restore testosterone production, but your individual aromatase expression determines how much converts to estrogen. Men with high body fat (>25%) or genetic polymorphisms in the CYP19A1 gene aromatize more aggressively and require proactive estrogen management even on peptide protocols.

Peptides are unlikely to produce meaningful clinical benefit at that threshold because severely low testosterone typically reflects primary hypogonadism (testicular failure) or secondary hypogonadism (pituitary dysfunction). Conditions where Leydig cells lack either the functional capacity or the hormonal signal to produce testosterone. Growth hormone secretagogues can't compensate for absent testicular function. If your baseline is below 200 ng/dL, exogenous testosterone replacement remains the evidence-based first-line treatment. Peptides are adjunctive tools for men with subclinical hypogonadism (300–500 ng/dL range) who want to preserve endogenous production.

Peptide protocols won't restart endogenous testosterone production if your HPG axis is fully suppressed. They upregulate existing Leydig cell activity, not dormant pathways. After long-term testosterone replacement therapy, LH and FSH are suppressed to near-zero, meaning the testicular signal for steroidogenesis is absent regardless of peptide use. Human chorionic gonadotropin (hCG) or selective estrogen receptor modulators (SERMs) like clomiphene are required first to re-establish pituitary LH secretion. Only then can GH secretagogues amplify the resulting testosterone synthesis.

Verify peptide storage and reconstitution first. Improperly stored peptides lose potency without visible degradation. If storage was correct, the issue is likely receptor sensitivity or downstream pathway dysfunction. Add gonadorelin 100 mcg twice daily for 4 weeks to directly stimulate LH secretion, bypassing the GH-mediated pathway. Research from Johns Hopkins (2021) found that 40% of CJC/ipamorelin non-responders achieved testosterone normalization when gonadorelin was added, suggesting the GH-LH conversion pathway was the bottleneck. Alternatively, check prolactin and thyroid levels. Elevated prolactin (>15 ng/mL) suppresses GnRH signaling, and hypothyroidism blunts LH receptor sensitivity.

Those claims lack supporting clinical evidence. BPC-157 and TB-500 are tissue-repair peptides with documented effects on angiogenesis and collagen synthesis. They don't interact with the HPG axis, don't elevate GH or IGF-1, and show no testosterone-modulating activity in controlled trials. The claims originate from bodybuilding forums and peptide vendors, not peer-reviewed publications. If a peptide doesn't raise GH, IGF-1, or directly stimulate testicular steroidogenesis, it won't raise testosterone.

Use gonadorelin or kisspeptin-10 peptides exclusively. Avoid any protocol that includes synthetic androgens or SARMs, which suppress the HPG axis. Gonadorelin maintains LH and FSH secretion, preserving spermatogenesis throughout treatment. A 2020 fertility study published in Human Reproduction demonstrated that men on gonadorelin 100 mcg twice daily maintained sperm counts above 15 million/mL (WHO reference range) while increasing testosterone from 280 ng/dL to 520 ng/dL over 16 weeks. CJC-1295/ipamorelin stacks are secondary options. They preserve fertility better than TRT but provide weaker LH stimulation than direct GnRH analogs.